PL1771192T3 - Stosowanie asparaginianu do regulowania poziomów glukozy we krwi - Google Patents

Stosowanie asparaginianu do regulowania poziomów glukozy we krwi

Info

Publication number
PL1771192T3
PL1771192T3 PL05762926T PL05762926T PL1771192T3 PL 1771192 T3 PL1771192 T3 PL 1771192T3 PL 05762926 T PL05762926 T PL 05762926T PL 05762926 T PL05762926 T PL 05762926T PL 1771192 T3 PL1771192 T3 PL 1771192T3
Authority
PL
Poland
Prior art keywords
aspartate
blood
glucose levels
regulating glucose
regulating
Prior art date
Application number
PL05762926T
Other languages
English (en)
Inventor
Robert Johan Joseph Hageman
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35714682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1771192(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Publication of PL1771192T3 publication Critical patent/PL1771192T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
    • A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
    • A23L13/424—Addition of non-meat animal protein material, e.g. blood, egg, dairy products, fish; Proteins from microorganisms, yeasts or fungi
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L23/00—Soups; Sauces; Preparation or treatment thereof
    • A23L23/10—Soup concentrates, e.g. powders or cakes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pediatric Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
PL05762926T 2004-07-19 2005-07-18 Stosowanie asparaginianu do regulowania poziomów glukozy we krwi PL1771192T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58879304P 2004-07-19 2004-07-19
EP04077100 2004-07-19
EP04077359 2004-08-20
PCT/NL2005/000519 WO2006009437A2 (en) 2004-07-19 2005-07-18 Use of aspartate for regulating glucose levels in blood
EP05762926.3A EP1771192B1 (en) 2004-07-19 2005-07-18 Use of aspartate for regulating glucose levels in blood

Publications (1)

Publication Number Publication Date
PL1771192T3 true PL1771192T3 (pl) 2019-02-28

Family

ID=35714682

Family Applications (3)

Application Number Title Priority Date Filing Date
PL05762925T PL1771191T3 (pl) 2004-07-19 2005-07-18 Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych
PL05762926T PL1771192T3 (pl) 2004-07-19 2005-07-18 Stosowanie asparaginianu do regulowania poziomów glukozy we krwi
PL13152810T PL2705849T3 (pl) 2004-07-19 2005-07-18 Preparat do zastosowania asparaginianu do regulowania poziomu glukozy we krwi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL05762925T PL1771191T3 (pl) 2004-07-19 2005-07-18 Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13152810T PL2705849T3 (pl) 2004-07-19 2005-07-18 Preparat do zastosowania asparaginianu do regulowania poziomu glukozy we krwi

Country Status (13)

Country Link
US (5) US8003600B2 (pl)
EP (3) EP1771191B1 (pl)
JP (2) JP2008506771A (pl)
CN (3) CN103734746B (pl)
BR (2) BRPI0513500C8 (pl)
CA (2) CA2574360A1 (pl)
DK (2) DK2705849T3 (pl)
ES (3) ES2700463T3 (pl)
NZ (1) NZ552706A (pl)
PL (3) PL1771191T3 (pl)
RU (1) RU2633071C2 (pl)
TR (1) TR201809368T4 (pl)
WO (2) WO2006009438A2 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1771191T3 (pl) * 2004-07-19 2014-08-29 Nutricia Nv Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych
TW200616546A (en) * 2004-09-29 2006-06-01 Asama Kasei Kk A function composition or food containing a whey protein, an antibody from milk or an antibody
EP1853246A1 (en) * 2005-02-17 2007-11-14 Instituto del Metabolismo Celular, S.L. L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
BRPI0620465A2 (pt) * 2005-12-23 2011-11-16 Nutricia Nv uso de uma composição
JP5118125B2 (ja) * 2006-03-23 2013-01-16 ネステク ソシエテ アノニム 高カロリーの栄養補助食品
CA2665164A1 (en) * 2006-10-06 2008-05-15 Nestec S.A. Compositions and multiplex assays for measuring biological mediators of physiological health
WO2008054193A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
DK2044853T3 (da) 2007-10-02 2011-06-14 Isme Privates Forschungsinstitut Fuer Sport Medizin Und Ernaehrung Gmbh Næringsstof til anvendelse til accelereret fysiologisk præstationsforbedring
US8651126B2 (en) 2007-11-21 2014-02-18 Teva Pharmaceutical Industries, Ltd. Controllable and cleanable steam trap apparatus
WO2010002242A1 (en) 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
CA2676518A1 (en) * 2008-08-29 2010-02-28 Kraft Foods Global Brands Llc Whey protein pre-load
WO2010033425A2 (en) * 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
WO2010104374A1 (en) * 2009-03-09 2010-09-16 N.V. Nutricia Nutritional composition inducing a postprandial endocrine response
WO2010112060A1 (en) * 2009-03-30 2010-10-07 Isme Privates Forschungsinstitut Für Sport, Medizin Und Ernährung Gmbh Nutriment for use for accelerated physiological perfomance enhancement
CN102368913A (zh) 2009-04-01 2012-03-07 雀巢产品技术援助有限公司 降低肥胖的风险
US8703719B1 (en) * 2009-05-18 2014-04-22 Bio-Engineered Supplements And Nutrition, Inc. Method and composition for improved muscle performance
WO2011021926A1 (en) * 2009-08-21 2011-02-24 N.V. Nutricia Regulating the amino acid pool used for the acute-phase protein synthesis
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients
PH12013501773A1 (en) * 2011-03-31 2013-10-14 Nestec Sa Nutritional compositions for increasing arginine levels and methods of using same
US20140107193A1 (en) * 2011-10-14 2014-04-17 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of kaempferol and/or fisetin and uses thereof
EP2897472A1 (en) * 2012-09-21 2015-07-29 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
US10668037B2 (en) * 2012-12-06 2020-06-02 Bio Health Solutions, Llc Treatment for chronic kidney disease
US9669010B2 (en) * 2012-12-06 2017-06-06 Bio Health Solutions, Llc Treatment for chronic kidney disease
US20160000128A1 (en) * 2013-02-15 2016-01-07 Nestec S.A. Food composition and its use
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
US9226914B2 (en) * 2013-07-16 2016-01-05 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US9241923B2 (en) * 2013-07-16 2016-01-26 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US20150119322A1 (en) * 2013-07-31 2015-04-30 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US10709770B2 (en) * 2013-07-31 2020-07-14 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US9609888B2 (en) * 2013-07-31 2017-04-04 Mead Johnson Nutrition Company Nutritional compositions containing synergistic combination and uses thereof
US20150164833A1 (en) * 2013-12-17 2015-06-18 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of ursolic acid and uses thereof
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
RU2644355C1 (ru) * 2017-04-17 2018-02-09 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соединения на основе пиридоксина, обладающие способностью активировать фермент глюкокиназу
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
US11255838B2 (en) 2017-11-03 2022-02-22 Lysulin, Inc. Levels, functions, and resistances related to chronic conditions by using lysine-based supplements
US10610544B2 (en) 2017-11-03 2020-04-07 Lysulin, Inc. Insulin resistance and beta cell function using lysine-based supplements
US10656166B2 (en) 2017-11-03 2020-05-19 Lysulin, Inc. Inhibiting chronic blood and nephrological disorders using lysine-based supplements
US10653720B2 (en) 2017-11-03 2020-05-19 Lysulin, Inc. Prevention of protein glycation using lysine/zinc supplements
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN110655567B (zh) * 2019-11-12 2021-07-09 云南大学 食品蛋白的磷酸化方法及其磷酸化蛋白
AU2020397933A1 (en) * 2019-12-05 2022-06-30 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
KR20250091590A (ko) * 2023-12-14 2025-06-23 의료법인 성광의료재단 아스파르트산을 포함하는 말초동맥질환의 예방 또는 치료용 약학적 조성물
WO2025235457A1 (en) 2024-05-09 2025-11-13 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1560000A (en) 1924-08-15 1925-11-03 Beatrice Sanville Garment button
US4138498A (en) 1976-12-07 1979-02-06 W. R. Grace & Co. Ruminant feed additive
US5116819A (en) 1989-05-05 1992-05-26 Clintec Nutrition Co. Enteral diet for patients with pulmonary disease
FR2657013B1 (fr) 1990-01-18 1992-05-15 Medgenix Group Sa Composition dietetique a base de polypeptides et acides amines.
US5292773A (en) 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
US5356873A (en) * 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
CA2143420C (en) * 1992-12-23 1999-01-19 Phyllis J. B. Acosta Medical foods for the nutritional support of infant/toddler metabolic diseases
US5470839A (en) 1993-04-22 1995-11-28 Clintec Nutrition Company Enteral diet and method for providing nutrition to a diabetic
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
GB9409646D0 (en) 1994-05-13 1994-07-06 Scient Hospital Suppl Int Ltd Nutritional formulation
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
JPH0965836A (ja) * 1995-08-31 1997-03-11 Hokuren Federation Of Agricult Coop:The α−グルコシダーゼ阻害剤、それを含む糖組成物、甘味料、食品及び飼料
MY115050A (en) 1995-10-16 2003-03-31 Mead Johnson Nutrition Co Diabetic nutritional product having controlled absorption of carbohydrate
WO1997042834A1 (en) 1996-05-13 1997-11-20 Gist-Brocades B.V. Novel food compositions
DE19632452C1 (de) * 1996-08-12 1998-02-19 Cpc International Inc Würzsauce, Verfahren zu deren Herstellung und deren Verwendung
WO1998008521A1 (de) * 1996-08-26 1998-03-05 Oswald Wiss Vitaminpräparate mit sauerstoffsparender wirkung bei körperlicher leistung
DE19701382A1 (de) 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
US6042834A (en) * 1997-01-29 2000-03-28 Baraka; Mohamed Wasif Herbal composition for diabetes and method of treatment
US5922766A (en) 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
RU2145869C1 (ru) * 1999-04-30 2000-02-27 Орещенко Андрей Владимирович Способ антимутагенного воздействия на организм
CA2274414A1 (en) 1999-06-11 2000-12-11 Universite Laval Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals
US6312755B1 (en) * 1999-07-16 2001-11-06 Ampc Whey treatment process for achieving high concentration of α-lactalbumin
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
GB9929497D0 (en) * 1999-12-14 2000-02-09 Vitaflo Limited Improved amino acid mixtures for the treatment and/or management of certain diseases
ZA200109677B (en) * 2000-09-06 2002-06-25 Technikon Pretoria A nutritional and pharmaceutical composition.
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6743770B2 (en) 2001-02-14 2004-06-01 Functional Foods, Inc. Nutritional supplement for the management of stress
CN1193691C (zh) * 2001-02-28 2005-03-23 陈胜利 中老年人养生保健饮料及制备方法
US6720312B2 (en) 2001-03-16 2004-04-13 Heartland Health Solutions, Llc Method for controlling the membrane structure of a starch granule
US20030000391A1 (en) 2001-06-12 2003-01-02 Jay Highman Organic nutritional formula
EP1443946A2 (en) 2001-07-03 2004-08-11 Nutri Pharma ASA Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030118663A1 (en) * 2001-12-24 2003-06-26 Ching-Ming Chang Method and composition for treating diabetes
US6916796B2 (en) 2002-06-12 2005-07-12 Abbott Laboratories Use of pullulan as a slowly digested carbohydrate
GB0213612D0 (en) * 2002-06-13 2002-07-24 Novartis Nutrition Ag Organic compounds
GB0221184D0 (en) 2002-09-13 2002-10-23 Cerestar Holding Bv Carbohydrate materials in food and drink compositions
US6706697B1 (en) * 2002-09-19 2004-03-16 Jason Pharmaceuticals, Inc. Diabetic nutrition and weight loss drink compositions
EP1571925A1 (en) * 2002-12-20 2005-09-14 Unilever N.V. Blood glucose regulating composition
PL1771191T3 (pl) * 2004-07-19 2014-08-29 Nutricia Nv Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych

Also Published As

Publication number Publication date
US20110288016A1 (en) 2011-11-24
PL2705849T3 (pl) 2018-09-28
TR201809368T4 (tr) 2018-07-23
CN101018561A (zh) 2007-08-15
CA2574423A1 (en) 2006-01-26
US8501676B2 (en) 2013-08-06
WO2006009438A3 (en) 2006-09-14
BRPI0513500B8 (pt) 2022-05-24
CN101022821B (zh) 2014-01-29
CA2574360A1 (en) 2006-01-26
BRPI0513551A (pt) 2008-05-06
BRPI0513500A (pt) 2008-05-06
NZ552706A (en) 2011-01-28
CN103734746A (zh) 2014-04-23
US9539278B2 (en) 2017-01-10
BRPI0513500C8 (pt) 2022-06-14
WO2006009437A2 (en) 2006-01-26
BRPI0513500B1 (pt) 2021-03-09
RU2010140355A (ru) 2012-04-10
EP1771191A2 (en) 2007-04-11
DK2705849T3 (en) 2018-05-22
CN103734746B (zh) 2017-01-11
RU2633071C2 (ru) 2017-10-11
DK1771191T3 (da) 2014-06-10
US9889149B2 (en) 2018-02-13
EP1771192A2 (en) 2007-04-11
US20150038453A1 (en) 2015-02-05
ES2467093T3 (es) 2014-06-11
JP2008506772A (ja) 2008-03-06
US8003600B2 (en) 2011-08-23
US20080032916A1 (en) 2008-02-07
US8865649B2 (en) 2014-10-21
JP2008506771A (ja) 2008-03-06
ES2673195T3 (es) 2018-06-20
EP1771192B1 (en) 2018-09-12
PL1771191T3 (pl) 2014-08-29
US20080269117A1 (en) 2008-10-30
US20140161928A1 (en) 2014-06-12
EP2705849B1 (en) 2018-04-04
WO2006009437A3 (en) 2006-04-06
CN101022821A (zh) 2007-08-22
WO2006009438A2 (en) 2006-01-26
EP2705849A3 (en) 2014-10-15
EP1771191B1 (en) 2014-03-12
ES2700463T3 (es) 2019-02-15
EP2705849A2 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
PL2705849T3 (pl) Preparat do zastosowania asparaginianu do regulowania poziomu glukozy we krwi
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP1731113A4 (en) MEDICAL TREATMENT KIT
EP1789109A4 (en) DIALYSIS IMPLANT AND METHODS OF USE
PL1979050T3 (pl) Leczenie chorób naczyń obwodowych z zastosowaniem komórek pochodzenia poporodowego
IL178151A0 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
PL378748A1 (pl) Zastosowanie selektywnych agonistów receptora EP2 w leczeniu
PL1957135T3 (pl) Urządzenie do automatycznej regulacji stężenia glukozy we krwi pacjenta z cukrzycą
IL180929A0 (en) The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
ZA200708312B (en) Stabilizing the activity of PQQ-dependent glucose dehydrogenase in electrochemical biosensors
GB0404656D0 (en) Treatment of spinal conditions
EP1829537A4 (en) PREPARATION FOR REDUCTION OF BODILY GREASE
IL192031A0 (en) Use of cicletanine and other furopyridines for treatment of hypertension
IL178827A0 (en) Use of reboxetine for the treatment of pain
EP1922063A4 (en) METHOD FOR TREATING PAIN IN PATIENTS
GB0426196D0 (en) Methods of treatment
GB2411834B (en) Composition for use in the treatment of dry skin conditions
GB0423173D0 (en) Treatment of diabetes
GB0701549D0 (en) Skin treatment
EP1804795A4 (en) ENANTIOMERIC COMPOSITIONS OF CICLETANINE, ALONE OR COMBINED WITH OTHER AGENTS, USED FOR THERAPEUTIC PURPOSES
AU2003240254A8 (en) Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
IL181785A0 (en) Use of epothilones in the treatment of bone metastasis
GB0509911D0 (en) Medical treatment aid for use in treating children
GB0400547D0 (en) Treatment of blood vessels